Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Find studies

Showing 26–48 of 48 studies in End-of-life care · tagged Clinical Trials (page 2 of 2) · 32,180 in the whole library · How the 0–100 score works

Download bibliography of these 48 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

What “End-of-life care” covers

End-of-life care — Hospice, palliative care and end-of-life decision-making for people living with dementia.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Family members of persons with advanced dementia may be asked to make complex treatment decisions without having adequate knowledge regarding the risks and benefits. 1 key finding →

Design: randomized controlled trial Evidence: high

Quality of life of people with advanced dementia living in nursing homes is often suboptimal. 1 key finding →

Design: randomized controlled trial Evidence: high

ACOVE Quality Indicators

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Annals of Internal Medicine 2001-10-16

A Systematic ReviewObstructive sleep apnoea, positive airway pressure treatment and postoperative delirium: protocol for a retrospective observational studyEvidence supporting the best clinical management of patients with multimorbidity and polypharmacy: a systematic guideline review and expert consensusDeprescribiendo para mejorar la salud de las personas o cuando deprescribir puede ser la mejor medicinaThe use of proton pump inhibitors among older adults with intellectual disability: A cross sectional observational studyNeed for Comprehensive Health Care Quality Measures for Older AdultsDevelopment and initial validation of prescribing quality indicators for patients with chronic kidney diseaseOlder patients' prescriptions screening in the community pharmacy: development of the Ghent Older People's Prescriptions community Pharmacy Screening (GheOP³S) toolA New Computer-Based Tool to Reduce Potentially Inappropriate Prescriptions in Hospitalized Geriatric PatientsThe Successful Aging After Elective Surgery Study: Cohort Description and Data Quality ProceduresRoutine deprescribing of chronic medications to combat polypharmacyAnnual Cognitive Assessment for Older Adults: Update for NursesThe impact of pharmaceutical care interventions for medication underuse in older people: a systematic review and meta-analysisAssessing appropriateness of osteoarthritis care using quality indicators: a systematic reviewCurrent Factors of Fragility and Delirium in Vascular SurgeryDrug-related problems identification in general internal medicine: The impact and role of the clinical pharmacist and pharmacologistPrescription of potentially inappropriate drugs for geriatric patients in long-term care: improvement through pharmacist's interventionChanging practice in dementia care in the community: developing and testing evidence-based interventions, from timely diagnosis to end of life (EVIDEM)High Prevalence of Poor Quality Drug Prescribing in Older Individuals: A Nationwide Report From the Italian Medicines Agency (AIFA)Delirium in elderly peopleDelphi consensus statement: Quality indicators for Inflammatory Bowel Disease Comprehensive Care UnitsPotentiality of STOPP/START criteria used in primary care to effectively change inappropriate prescribing in elderly patientsToo Much to ManageHip Fracture ManagementAppropriateness of Medication Prescribing Using the STOPP/START Criteria in Veterans Receiving Home-Based Primary CareActualización de la neumonía en el ancianoEstablishi 1 key finding →

Design: randomized controlled trial Evidence: high

The findings support the reliability and validity of the Resistiveness to Care Scale for use with older adults with dementia in nursing home settings. 5 key findings →

Design: randomized controlled trial Evidence: high

The facilitated approach explored in this study addressed known barriers to case conferencing. 1 key finding →

Design: randomized controlled trial Evidence: high

Florbetaben scans were assessed visually and quantitatively, and results were compared with amyloid plaque scores. 3 key findings →

Design: open-label trial Participants: 82 Evidence: low

Despite the increased interest in palliative care for patients with dementia there is currently little evidence on which to base such an approach. 1 key finding →

Design: randomized controlled trial Evidence: high

Successful strategies from other disciplines could be considered by palliative care researchers. 1 key finding →

Design: systematic review Evidence: high

Five hundred and forty five patients from 67 NH units were included and randomized to the intervention ( N = 297; 36 units) and control group ( N = 248; 31 units). 5 key findings →

Participants: 72 Evidence: high

An important goal of advance care planning (ACP) is ensuring that patients receive care concordant with their preferences. 5 key findings →

Design: randomized controlled trial Evidence: high

Among 40,074 inpatient encounters (median age 72 years [IQR 62-82], 46.9% male, 22.7% Black, 4.6% Hispanic), the most common serious illness was heart failure (66.0%), followed by COPD (39.3%), kidney failure (12.4%), cancer (12.3%), and dementia (11.6%). 5 key findings →

Design: randomized controlled trial Evidence: high

[(18)F]flutemetamol amyloid PET detects primarily advanced stages of Aβ pathology in preclinical and symptomatic AD cases. 1 key finding →

Design: clinical trial Participants: 68 Evidence: moderate

Absence of functional surrogate decision-makers is a major barrier to research and clinical decision-making for hospitalized patients with advanced dementia. 2 key findings →

Participants: 68 Evidence: high

Three cohorts of interdisciplinary scholars (N = 53) have started and two have completed DEM-PCCT. 5 key findings →

Design: longitudinal study Participants: 53 Evidence: moderate

We have enrolled 29 clinicians and 53 FCPs and aim to have 24 clinicians matched with 96 FCPs (N = 120) to complete the intervention. 3 key findings →

Participants: 120 Evidence: high

As of October 2025, we have recruited 200 participants. 4 key findings →

Participants: 200 Evidence: high

Various approaches to advance care planning are in use and generally acceptable also for persons with dementia and their care partners. 1 key finding →

Design: randomized controlled trial Evidence: high

The decision-support intervention piloted in this study was feasible and relevant for surrogate decision-makers of persons with advanced dementia in NHs, and it improved quality of communication between SDM and NH providers. 1 key finding →

Evidence: high

A greater number of needs (B=.42), polypharmacy (B=.33), and unmanaged symptoms (B=.31) significantly predicted higher triage priority (p<.001). 1 key finding →

Participants: 461 Evidence: low

We included 21 ACP RCTs. Trials included 103 outcome measures (39 primary and 64 secondary), of which 11% measured process, 14% measured action, 49% measured healthcare, and 26% measured quality of care. 5 key findings →

Participants: 21 Evidence: high

The Dementia Palliative Care Clinical Trials Training Program

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Innovation in Aging 2025-12-01

Of these, a growing number have secured funding, initiated collaborations, contributed to dementia palliative care research, and increased confidence and comfort with conducting clinical trials (p<.05). 5 key findings →

Evidence: moderate

Phase 1 (realist review; 86 papers) identified that a key intervention component was the activities enabling the development of moments of connection. 1 key finding →

Design: randomized controlled trial Participants: 32 Evidence: high

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomized / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multicenter collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 32,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 32,180 records, built mostly from automated pulls of Europe PMC (66.5% of the library) and OpenAlex (15.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,045 records (3.2% of the library) are not peer-reviewed — 966 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events

Last updated